clinical_trials
[Department of Error] Department of Error
Confidence96·multiple reportsImportance98NP-EVT-20261114-7142082
Slomovitz BM, Zhu J, Yin R, et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial. Lancet 2026; 408: 2081–96—In this Article, the numbers of patients that received subsequent therapies were incorrect and have been updated. Additionally, an updated appendix fil
Read the original at the primary source
[Department of Error] Department of Error
11/14/2026, 12:00:00 AM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —